Alnylam Pharmaceuticals ALNY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AMVUTTRA | $2.89B+167% | $2.31B+138% | $1.77B+106% | $1.35B+79.8% | $1.09B+66.6% | |
| GIVLAARI | $315.91M+19.3% | $308.49M+20.6% | $286.34M+14.3% | $283.51M+21.3% | $264.78M+15.4% | |
| ONPATTRO | $143.78M-38.3% | $172.79M-31.7% | $197.21M-28.5% | $208.42M-32.1% | $233.13M-27.4% | |
| OXLUMO | $200.67M+20.5% | $191.44M+14.6% | $185.36M+18.7% | $172.75M+19.4% | $166.49M+29.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alnylam Pharmaceuticals break its business down?
- Alnylam Pharmaceuticals (ALNY) reports total revenues by product across 4 parts — AMVUTTRA, GIVLAARI, ONPATTRO and OXLUMO. Each is extracted from the segment footnotes and tracked over time.
- Where does Alnylam Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alnylam Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
